RxDoctor Payments Data

Andrew Pettit, NP

Family · Murray, UTNPI 1487200853

Payments from drug & device makers

$2,976in general payments, 2019–2025

Across 144 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$891
  • AbbVie$484
  • Lilly USA, LLC$414
  • AstraZeneca$144
  • Bayer$104
  • Boston Scientific$76
  • plus $861 from 28 others

What the payments were for

  • Food & beverage$2,976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,976 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$16,723
Medicare patients
61
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide23$31,315
OzempicSemaglutide16$16,384
Aimovig AutoinjectorErenumab-Aooe11$7,747
Duloxetine Hcl20$659
Atorvastatin Calcium96$648
Levothyroxine Sodium63$569
Albuterol Sulfate HfaAlbuterol Sulfate20$542
Omeprazole38$406
Gabapentin22$393
Bupropion XlBupropion Hcl13$282
Amlodipine Besylate39$237
Lisinopril61$214
Losartan Potassium28$185
Hydrochlorothiazide17$108
Metformin Hcl11$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$891$47,69939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.

Other family in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →